☆ 4.2 Article

Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era

HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5

Huiping Shuai et al.

Summary: The study found that the BA.5 sublineage of Omicron has the strongest replication capacity in the human nasal epithelium, while its replication and pathogenicity are attenuated in the lungs. However, severe lung manifestations still occur in immunocompromised individuals and the elderly infected with Omicron sublineages.

EBIOMEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Bo Meng et al.

Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.

NATURE (2022)

Add to Collection

Letter Oncology

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC

Ludovic Jondreville et al.

Summary: Since the emergence of the Omicron variant of SARS-CoV-2, high hospitalization and death rates have been observed among immunocompromised patients, especially those who respond poorly to vaccination. A retrospective multicentric study found that pre-exposure prophylaxis with AZD7442 could effectively prevent COVID-19 infections in adult allogeneic hematopoietic stem cell transplant recipients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Letter Hematology

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Ola Blennow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study

Vincenzo Marasco et al.

Summary: In this multicentre retrospective study, researchers collected data from 91 patients with haematological malignancies and found that anti-spike neutralizing monoclonal antibodies can reduce the clinical progression and time to viral clearance of COVID-19 in immunosuppressed patients.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

Anne-Gaelle Goubet et al.

Summary: Patients with cancer are at higher risk of severe COVID-19, with malignant diseases favoring increased and prolonged viral RNA shedding accompanied by immune pathology changes. Virus-induced lymphopenia exacerbates cancer-associated lymphocyte loss, which is correlated with chronic viral shedding, COVID-19 severity, and higher risk of cancer-related death.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Oncology

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain

Josep-Maria Ribera et al.

Summary: The study compared the characteristics and outcomes of adults with acute lymphoblastic leukemia (ALL) and COVID-19 infection in the first and second waves of the pandemic in Spain. The presence of comorbidities at COVID-19 infection was identified as the only prognostic factor for survival, highlighting the importance of vaccination priority for these patients.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Tomas Palanques-Pastor et al.

Summary: This multicenter observational study found a higher mortality rate in AML patients with SARS-CoV-2 infection. Factors influencing mortality included age, gender, active leukemia, severity of symptoms, etc. Certain medications and biochemical markers may have a protective effect in lowering the mortality rate.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Letter Hematology

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

Gordon Cook et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Oncology

COVID-19 in persons with haematological cancers

Wenjuan He et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio Garcia-Suarez et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

Add to Collection

Article Hematology

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Ajai Chari et al.

BLOOD (2020)

Add to Collection

Article Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A. Wood et al.

BLOOD ADVANCES (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.